Your activity: 119 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Manganese: Drug information

Manganese: Drug information
(For additional information see "Manganese: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Mangimin [OTC] [DSC];
  • MN-50 [OTC]
Brand Names: Canada
  • Micro-Mn
Pharmacologic Category
  • Dietary Supplement;
  • Trace Element, Parenteral
Dosing: Adult
Dietary supplement

Dietary supplement: Oral: 1 capsule/tablet daily.

Parenteral nutrition, maintenance requirement

Parenteral nutrition, maintenance requirement:

Note: Parenteral nutrition ordering requires advanced knowledge of nutrient and other metabolic requirements and should only be prescribed by clinicians trained in assessment and order writing for parenteral nutrition (ASPEN [Guenter 2015]).

Standard daily manganese requirement : IV: Elemental manganese 55 mcg daily as component of parenteral nutrition; adjust daily dose based on serum manganese and clinical considerations (ASPEN 2019).

Dosing: Kidney Impairment: Adult

Use caution; manganese chloride solution for injection contains aluminum.

Dosing: Hepatic Impairment: Adult

Use caution; dose may need to be decreased or withheld in patients with elevated bilirubin or confirmed cholestatic disease.

Dosing: Pediatric
Parenteral nutrition, maintenance requirement

Parenteral nutrition, maintenance requirement: IV: 2 to 10 mcg/kg/day

Expert recommendations suggest decreasing the daily dose for infants and children to 1 mcg/kg/day (up to a maximum of 50 mcg/day). However, these recommendations are difficult to follow with the current sources of parenteral manganese (ASPEN [Vanek 2012]).

Note: Use caution in premature neonates; manganese chloride solution for injection contains aluminum.

Dosing: Kidney Impairment: Pediatric

Use caution; manganese chloride solution for injection contains aluminum.

Dosing: Hepatic Impairment: Pediatric

Use caution; dose may need to be decreased or withheld in patients with elevated bilirubin or confirmed cholestatic disease.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as chelated:

MN-50: Elemental manganese 16.67 mg

Solution, Intravenous, as chloride:

Generic: Elemental manganese 0.1 mg/mL (10 mL)

Solution, Intravenous, as sulfate [preservative free]:

Generic: Elemental manganese 0.1 mg/mL (10 mL [DSC])

Tablet, Oral, as chelated:

Mangimin: Elemental manganese 10 mg [DSC] [corn free, rye free, wheat free]

Generic: Elemental manganese 15 mg [DSC], Elemental manganese 50 mg

Tablet, Oral, as gluconate:

Generic: 50 mg [elemental manganese 5.7 mg]

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as sulfate:

Micro-Mn: Elemental manganese 0.1 mg/mL (10 mL)

Administration: Adult

Oral: May be administered with a meal.

IV: Do not administer IM or by direct IV injection; acidic pH of the solution may cause tissue irritations and it is hypotonic; administer after dilution in volume of fluid ≥100 mL.

Administration: Pediatric

Parenteral: Not for direct IV or IM injection; must be diluted in parenteral nutrition solution prior to administration; acidic pH of the solution may cause tissue irritation and it is hypotonic

Use: Labeled Indications

Dietary supplementation: Trace element added to parenteral nutrition to prevent manganese deficiency; orally as a dietary supplement.

Medication Safety Issues
Sound-alike/look-alike issues:

Manganese sulfate may be confused with magnesium sulfate

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.

Contraindications

There are no contraindications listed within the manufacturer's US labeling.

Canadian labeling: Hypersensitivity to manganese or any component of the formulation.

Warnings/Precautions

Disease-related concerns:

• Biliary tract impairment: Use with caution in patients with biliary tract impairment; dose may need to be decreased or withheld.

• Hepatic impairment: Use with caution in patients with hepatic impairment; dose may need to be decreased or withheld.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.

Other warnings/precautions:

• Appropriate use: Due to its highly acidic pH (pH 2.0), direct IV or IM injection is contraindicated; may result in severe tissue damage.

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Animal reproduction studies have not been conducted. Manganese crosses the placenta and can be detected in placental tissue and cord blood (Osada 2002).

Breastfeeding Considerations

Manganese is found in breast milk. Normal concentrations of manganese in human milk are generally lower than cow's milk or those found in food sources, but absorption from human milk is higher (IOM 2004).

Dietary Considerations

Dietary adequate intake (IOM 2001):

0 to 6 months: 0.003 mg/day

7 to 12 months: 0.6 mg/day

1 to 3 years: 1.2 mg/day

4 to 8 years: 1.5 mg/day

9 to 13 years: Males: 1.9 mg/day; Females: 1.6 mg/day

14 to 18 years: Males: 2.2 mg/day; Females: 1.6 mg/day

>18 years: Males: 2.3 mg/day; Females: 1.8 mg/day

Pregnancy: 2 mg/day

Lactation: 2.6 mg/day

Monitoring Parameters

Periodic manganese plasma level

Reference Range

Whole blood: 6 to 12 mcg/L.

Mechanism of Action

Cofactor in many enzyme systems, stimulates synthesis of cholesterol and fatty acids in liver, and influences mucopolysaccharide synthesis

Pharmacokinetics

Absorption: Poor

Distribution: Concentrated in mitochondria of pituitary gland, pancreas, liver, kidney, and bone

Excretion: Bile (primarily); urine (negligible)

Pricing: US

Solution (Manganese Chloride Intravenous)

0.1 mg/mL (per mL): $3.06

Tablets (Manganese Gluconate Oral)

50 mg (per each): $0.06

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Bothdel (JP);
  • Infladase Forte (IN)


For country code abbreviations (show table)
  1. American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition. http://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-FINAL.pdf. Published January 8, 2019.
  2. Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.
  3. Guenter P, Boullata JI, Ayers P, et al; Parenteral Nutrition Safety Task Force, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). Standardized competencies for parenteral nutrition prescribing: the American Society for Parenteral and Enteral Nutrition model. Nutr Clin Pract. 2015;30(4):570-576. doi:10.1177/0884533615591167 [PubMed 26078288]
  4. Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academies Press; 2001. https://www.ncbi.nlm.nih.gov/books/NBK222310/
  5. Manganese 50 mg capsules [prescribing information]. Salt Lake City, UT: Solaray; received October 2022.
  6. Manganese 50 mg tablets [prescribing information]. Ronkonkoma, NY; PipingRock; received October 2022.
  7. Manganese chloride injection [prescribing information]. Lake Forest, IL: Hospira Inc; April 2021.
  8. MICRO MN (manganese) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; January 2022.
  9. Osada H, Watanabe Y, Nishimura Y, et al, "Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth," Acta Obstet Gynecol Scand, 2002, ;81(10):931-7. [PubMed 12366483]
  10. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27:440-491. [PubMed 22730042]
Topic 9586 Version 133.0